Tags : r/r DLBCL

MorphoSys Reports Submission of Tafasitamab’s BLA to the US FDA

Shots: The BLA submission is based on L-MIND P-II trial data results assessing Tafasitamab + lenalidomide in patients with r/r DLBCL and retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received Tafasitamab + lenalidomide vs lenalidomide monothx Re-MIND has met its 1EPs and has shown improved ORR of the […]Read More